Cited by 624Pharmacology and Obesity TreatmentBioactive natural compoundsMedicinal Plant Research

Possible anti-obesity therapeutics from nature--a review

Yun, Jong Won·2010·Phytochemistry

Abstract

Obesity is associated with many diseases, particularly diabetes, hypertension, osteoarthritis, and heart disease. The obesity incidence has increased at an alarming rate in recent years, becoming a worldwide health problem, with incalculable social costs. Two different obesity-treatment drugs are currently on the market: orlistat, which reduces intestinal fat absorption via inhibiting pancreatic lipase; and sibutramine, an anorectic or appetite suppressant. Both drugs have hazardous side-effects, including increased blood pressure, dry mouth, constipation, headache, and insomnia. For this reason, a wide variety of natural materials have been explored for their obesity treatment potential. These are mainly complex products having several components with different chemical and pharmacological features. This review aimed to survey the literature covering natural products with anti-obesity activity and to review the scientific data, including experimental methodologies, active components, and mechanisms of action against obesity.

Integrity signals

Registry

Crossref · 10.1016/j.phytochem.2010.07.011

Cites

294 of 294 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Yun, J. W.
Affiliations
Daegu University (KR)
Corresponding author
Yun, Jong Won
Venue
Phytochemistry
Publisher
Elsevier BV
Published
2010-10
Volume
71
Issue
14-15
Pages
1625-1641
ISSN
0031-9422 (ISSN-L)
OpenAlex
W2167277714
Cited by
619
References
294
Citations by year
2026: 7 · 2025: 21 · 2024: 25 · 2023: 29 · 2022: 50 · 2021: 40 · 2020: 37 · 2019: 55 · 2018: 57 · 2017: 49 · 2016: 64 · 2015: 50 · 2014: 47 · 2013: 37 · 2012: 36
FWCI
3.17
Type
journal article
Language
en
Open access
closed
Locations
  • Phytochemistry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioactive natural compounds
  • Life Sciences › Agricultural and Biological Sciences › Plant Science › Medicinal Plant Research
Keywords
obesity, anti-obesity drugs, natural products, orlistat, sibutramine, pancreatic lipase inhibition, appetite suppressants, mechanism of action, obesity-related comorbidities
MeSH terms
Appetite Depressants, Biological Products, Energy Metabolism, Lipase, Obesity, Plants, Medicinal, Adipocytes, Anti-Obesity Agents, Lipid Metabolism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review